An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

Therapeutic anticancer vaccines are designed to boost patients’ immune responses to tumors. One approach is to use a viral vector to deliver antigen to in situ DCs, which then activate tumor-specific T cell and antibody responses. However, vector-specific neutralizing antibodies and suppressive cell...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Morse, Michael A., Hobeika, Amy C., Osada, Takuya, Berglund, Peter, Hubby, Bolyn, Negri, Sarah, Niedzwiecki, Donna, Devi, Gayathri R., Burnett, Bruce K., Clay, Timothy M., Smith, Jonathan, Lyerly, H. Kim
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2010
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2929723/
https://ncbi.nlm.nih.gov/pubmed/20679728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI42672
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים